Navigation Links
SAGE Labs, Inc. Licenses CRISPR/Cas9 genome engineering technology from Caribou Biosciences, Inc.
Date:9/24/2013

ST. LOUIS, Sept. 24, 2013 /PRNewswire/ -- SAGE Labs, Inc., a leading provider of in vivo products, services and technologies in the field of genome engineering, announced today that it has entered into a partnership and licensing agreement with Caribou Biosciences, Inc. (Caribou Bio) for key intellectual property related to the CRISPR/Cas9 genome editing system.

Under the agreement, SAGE Labs will gain exclusive rights to Caribou Bio's intellectual property to produce and sell genetically engineered rats, and will gain non-exclusive rights for mouse and rabbit models.  The Cas9 system will complement SAGE's Zinc Finger Nuclease (ZFN) technology, allowing SAGE to offer customers access to novel animal models of human disease, as well as reduced turnaround times for its custom model creation platform, SAGEspeed®.

"SAGE Labs is the leader in creation of next-generation research models. As such, it is important to have access to key technologies needed to perform complex genome engineering projects," commented Dr. David Smoller, CEO of SAGE Labs. "Using Cas9 allows us to provide our customers with enhanced models that provide the most translational value for their research."

"We believe the Cas9 system will become very important in the creation of new models of human disease, both in vitro and in vivo," commented Dr. Rachel Haurwitz, CEO of Caribou Bio. "SAGE Labs' track record as a market leader in commercializing in vivo technologies will enable them to use Cas9-based engineering to bring innovative, high-quality engineered research models to the marketplace."

Please see www.sageresearchlabs.com for further details.

About SAGE Labs

SAGE® Labs is a world-class provider of next-generation research models and transgenic support services. Using proprietary platform technologies, such as Zinc Finger Nucleases (ZFN) and the CRISPR/Cas9 system for genome engineering, SAGE produces complex in vivo research models in half the time as models produced using conventional technologies. For more information, visit http://www.sageresearchlabs.com.

About Caribou Bio

Caribou Bio specializes in the research and development of technologies for cellular engineering and analysis. Caribou Bio's technologies are based on the unique capabilities of Cas enzymes from the CRISPR prokaryotic immune system. Caribou Bio's lead technology is the Cas9 enzyme, a highly efficient and easy to use genome editing platform that does not require unique protein development.

Media Contact:
Phil Simmons
(314) 313-7847
Phil.Simmons@sageresearchlabs.com

 


'/>"/>
SOURCE SAGE Labs, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. LABS, Inc. Earns AABB Accreditation for Donor Testing
2. LABS, Inc. Among Colorados Top Private Companies
3. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
4. Sigma Life Science Licenses CompoZr Zinc Finger Nuclease Technology to Horizon Discovery
5. Genomatica Licenses TeselaGen Software for DNA Design
6. Empire Genomics Licenses Novel DNA Biomarker for Use in Diagnosing and Creating a Companion Diagnostic Test for Neuroendocrine Prostate Cancer
7. SRI International Licenses Bed Bug Detection Technology to Redcoat, a Virginia-Based Start-Up Company
8. Personal Genome Diagnostics Inc. Licenses Genome-Mapping Technology from Johns Hopkins University and Expands Its Cancer Genome Analysis Business
9. Genomas Expands Personalized Medicine Business with Clinical Laboratory Licenses in New York, Florida, California
10. Syngenta Licenses Plant Sensory Systems' Technology
11. Bluechiip Licenses Its Technology in Deal with US Tech Company MiTeGen
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... , January 23, 2017 ... Model Market by Type (Genetic, Cell-based (CD34, PBMC, BLT)), ... End User (Pharmaceutical & Biotech Companies, CRO) - Global ... the global Humanized Mouse Model Market for the forecast ... to reach USD 116.0 Million by 2021 from USD ...
(Date:1/24/2017)... , Jan. 23, 2017 /PRNewswire/ - BioAmber Inc. (NYSE: ... entered into an underwriting agreement with Rodman & Renshaw, ... LLC, as sole book running manager and representative of several ... on a firm commitment basis a minimum of 2,105,264 ... warrants to purchase a minimum of 1,052,632 shares of ...
(Date:1/23/2017)... N.J. , Jan. 23, 2017   Enteris ... feasibility study agreement with Sanofi to leverage ... delivery platform, Peptelligence™, to develop an oral formulation of ... Joel Tune , Chief Executive Officer and Executive ... is further validation of the tremendous value our Peptelligence ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... Vice President, Preclinical Safety and Senior Director, Safety Pharmacology. Dr. Thomas earned ... , Dr. Thomas’ career as an academic and industry preclinical drug developer ...
Breaking Biology Technology:
(Date:12/19/2016)... , España y TORONTO , 19 de diciembre ... Northern Biologics Inc. que permitirá el desarrollo acelerado de MSC-1, un ... en varios tipos de tumor en 2017, con múltiples sitios previstos ... ... clase con objetivo en el factor inhibidor de leucemia (LIF), una ...
(Date:12/15/2016)... , Dec. 15, 2016   WaferGen Bio-systems, ... held genomics technology company, announced today that on December ... Qualifications Department of The Nasdaq Stock Market LLC which ... bid price of WaferGen,s common stock had been at ... WaferGen has regained compliance with Listing Rule 5550(a)(2) of ...
(Date:12/12/2016)... 12, 2016  Researchers at Trinity College, Dublin, ... by combining the material with Silly Putty. The mixture ... detector able to sense pulse, blood pressure, respiration, ... The research team,s findings were ... here:  http://science.sciencemag.org/content/354/6317/1257 ...
Breaking Biology News(10 mins):